Cannabinoid Receptor Type 2 (CB2) Agonists Pipeline Insights 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Cannabinoid Receptor Type 2 (CB2) Agonists - Pipeline Insights, 2017" drug pipelines to their offering.

Cannabinoid Receptor Type 2 (CB2) Agonists - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Cannabinoid Receptor Type 2 (CB2) Agonists. This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Cannabinoid Receptor Type 2 (CB2) Agonists.

This report also assesses the Cannabinoid Receptor Type 2 (CB2) Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope:

  • The report provides competitive pipeline landscape of Cannabinoid Receptor Type 2 (CB2) Agonists
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Cannabinoid Receptor Type 2 (CB2) Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Cannabinoid Receptor Type 2 (CB2) Agonists and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Cannabinoid Receptor Type 2 (CB2) Agonists Overview
  2. Cannabinoid Receptor Type 2 (CB2) Agonists Pipeline Therapeutics
  3. Cannabinoid Receptor Type 2 (CB2) Agonists Therapeutics under Development by Companies
  4. Cannabinoid Receptor Type 2 (CB2) Agonists Filed and Phase III Products
  5. Cannabinoid Receptor Type 2 (CB2) Agonists Phase II Products
  6. Cannabinoid Receptor Type 2 (CB2) Agonists Phase I and IND Filed Products
  7. Cannabinoid Receptor Type 2 (CB2) Agonists Discovery and Pre-Clinical Stage Products
  8. Drug Candidate Profiles
  9. Cannabinoid Receptor Type 2 (CB2) Agonists - Therapeutics Assessment
  10. Companies Involved in Therapeutics Development for Cannabinoid Receptor Type 2 (CB2) Agonists
  11. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/88pq96/cannabinoid

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs